SGMTSagimet Biosciences Inc.同业对比
Sagimet Biosciences Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGMT本股 | — | — | — | — | — | -12.0%#4 | -2844.5%#5 | -19.9%#2 | — | — | 65.3%#3 | — |
| RMHI | — | — | — | — | — | -116.8%#8 | — | — | — | — | — | — |
| RPRX | — | 31.7x#1 | — | — | 5.1%#3 | -10.2%#3 | 65.6%#1 | 7.9%#1 | 8.7%#1 | — | 64.9%#4 | — |
| RVRC | — | — | — | — | — | — | — | -243.7%#8 | — | — | — | — |
| SDGR | — | — | — | — | 23.3%#2 | 44.8%#1 | -65.2%#3 | -31.4%#4 | — | — | 53.8%#5 | — |
| SKVI | — | — | — | — | 0.0%#4 | -88.1%#5 | -2481.6%#4 | — | — | — | — | — |
| SLGL | $182M#4 | — | 8.0x#1 | 9.4x#1 | 68.0%#1 | 42.1%#2 | -38.9%#2 | -26.9%#3 | -9.8%#2 | — | 171.9%#1 | — |
| SLN | $1.8B#3 | — | 46.8x#3 | 3224.0x#2 | -98.7%#5 | -95.6%#6 | -16292.8%#6 | -230.3%#6 | — | — | 155.3%#2 | — |
| SLNCF | — | — | — | — | -98.7%#5 | -95.6%#6 | -16292.8%#6 | -230.3%#6 | — | — | — | — |
| SMMT | $14.1B#2 | — | 22.4x#2 | — | — | -387.8%#9 | — | -171.4%#5 | — | — | -8.1%#6 | — |
| SMNR | — | — | — | — | — | -3320.4%#10 | — | — | — | — | — | — |
| SMNRW | — | — | — | — | — | -3320.4%#10 | — | — | — | — | — | — |
| SNY | $52.6B#1 | — | — | — | — | — | — | — | — | — | -9.6%#7 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议